Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Enbrel is a prescription tumor necrosis factor blocker containing etanercept. Adult indications include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. Pediatric indications include polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis from age 2 and plaque psoriasis from age 4.
read more about enbrel ...Etanercept is a soluble form of the p75 tumor necrosis factor receptor. It binds TNF-alpha and TNF-beta and prevents these inflammatory cytokines from binding to cell-surface TNF receptors. Reduced TNF signaling decreases inflammatory activity involved in several joint and skin diseases.
Enbrel treats moderate to severe rheumatoid arthritis, psoriatic arthritis, active ankylosing spondylitis, and chronic moderate to severe plaque psoriasis in adults. Pediatric uses include moderate to severe polyarticular juvenile idiopathic arthritis from age 2, juvenile psoriatic arthritis from age 2, and plaque psoriasis from age 4.
Adults with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis receive 50 mg subcutaneously once weekly. Adult plaque psoriasis starts at 50 mg twice weekly for three months, followed by 50 mg once weekly. Pediatric pJIA, plaque psoriasis, and juvenile psoriatic arthritis use 0.8 mg per kg weekly up to 50 mg.
Enbrel carries a boxed warning for serious infections and malignancies. Reported infections include tuberculosis, bacterial sepsis, invasive fungal infections, and other opportunistic infections. Other serious concerns include demyelinating disease, new or worsening heart failure, blood-cell disorders, hepatitis B reactivation, severe allergic reactions, and autoimmune hepatitis. Sepsis is a contraindication.
Enbrel is a tumor necrosis factor blocker containing the fusion protein etanercept.
The recommended adult rheumatoid arthritis dose is 50 mg by subcutaneous injection once weekly.
Yes. Patients are evaluated for active tuberculosis and tested for latent infection before treatment.
Yes. The boxed warning covers serious infections and malignancies associated with TNF-blocking treatment.
ENBREL (Etanercept) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a002b40c-097d-47a5-957f-7a7b1807af7f. Date Accessed September 29, 2026.
ENBREL Full Prescribing Information. https://www.pi.amgen.com/united_states/enbrel/derm/enbrel_pi.pdf. Date Accessed September 29, 2026.
Etanercept. https://www.ncbi.nlm.nih.gov/books/NBK545252/. Date Accessed September 29, 2026.
Etanercept Injection: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a602013.html. Date Accessed September 29, 2026.
Purple Book Product Details for Enbrel. https://purplebooksearch.fda.gov/index.cfm?blaNo=103795&event=productdetails. Date Accessed September 29, 2026.